SEARCHMETA-ANALYSISendocrinology, internal medicine

meta-analysis·endocrinology, internal medicine, meta-analysis, systematic review, clinical trial·PMC10159347

Weight loss efficiency and safety of tirzepatide: A Systematic review

PLOS ONE · 9 authors, 7 centres

AI SUMMARY

FIDELITY 100%

This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.

AGENT 01 · STRUCTURED SUMMARY

TRACE TO SOURCE

“

TL;DR

This systematic review and meta-analysis pooled data from 10 randomized controlled trials involving 9,873 patients with T2DM or obesity.

Full summary

861 CHARS

This systematic review and meta-analysis pooled data from 10 randomized controlled trials involving 9,873 patients with T2DM or obesity. The primary outcome was body weight change, with secondary outcomes including safety profiles. Tirzepatide demonstrated significant weight loss compared to placebo (-9.81 kg), GLP-1 receptor agonists (-1.05 kg), and insulin (-1.93 kg). Dose-response analyses showed significant reductions for all tirzepatide doses. Gastrointestinal adverse events (diarrhea, nausea, vomiting) were more frequent with tirzepatide than with placebo or basal insulin but were similar to GLP-1 receptor agonists. Limitations include the inclusion of industry-funded studies and that most trials focused on T2DM populations. The findings suggest tirzepatide is effective for weight loss but requires monitoring for gastrointestinal side effects.

STUDY TYPE

meta-analysis

SPECIALTY

endocrinology

SUMMARISED BY

AI pipeline

FIDELITY CHECK

100% · A

ORIGINAL PAPER

PMC10159347

Weight loss efficiency and safety of tirzepatide: A Systematic review

PLOS ONE

READ THE FULL PAPER

ABSTRACT

Objective Tirzeptide is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drug, which shows good efficiency for weight loss. Therefore, we aim to investigate the efficacy and safety of tirzepatide for weight loss in type 2 diabetes mellitus (T2DM) and obesity patients in this meta-analysis study. Methods Cochrane Library, PubMed, Embase, Clinical Trials, and Web of Science were searched from inception to October 5, 2022. All randomized controlled trials (RCTs) were included. The odds ratio (OR) was calculated using fixed-effects or random-effects models by Review Manager 5.3 software. Results In total, ten studies (12 reports) involving 9,873 patients were identified. A significant loss body weight in the tirzepatide group versus the placebo by -9.81 kg (95% CI (-12.09, -7.52), GLP-1 RAs by -1.05 kg (95% CI (-1.48, -0.63), and insulin by -1.93 kg (95% CI (-2.81, -1.05), respectively. In sub-analysis, the body weight of patients was significantly reduced in three tirzepatide doses (5 mg, 10 mg, and 15 mg) when compared with those of the placebo/GLP-1 RA/insulin. In terms of safety, the incidence of any adverse events and adverse events leading to study drug discontinuation was higher in the tirzepatide group, but the incidence of serious adverse events and hypoglycaemia was lower. Additionally, the gastrointestinal adverse events (including diarrhea, nausea, vomiting and decreased appetite) of tirzepatide were higher than those of placebo/basal insulin, but similar to GLP-1 RAs. Conclusion In conclusion, tirzeptide can significantly reduce the weight of T2DM and patient with obesity, and it is a potential therapeutic regimen for weight-loss, but we need to be vigilant about its gastrointestinal reaction.

CITATION EXPORT

Fei Lin, Bin Yu, Baodong Ling et al.. Weight loss efficiency and safety of tirzepatide: A Systematic review. PLOS ONE. (2023). https://doi.org/10.1371/journal.pone.0285197

AUTHORS

9 · 7 CENTRES

Fei Lin, Bin Yu, Baodong Ling, Guangyao Lv, Huijun Shang, Xia Zhao, Xiaoling Jie, Jing Chen, Yan Li

1 Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China
2 Clinical Medical College, Chengdu Medical College, Chengdu, China
3 Department of Pharmacy, Mianyang Central Hospital, Mianyang, China
4 School of Pharmacy, Chengdu Medical College, Chengdu, China
5 Department of Pharmacy, Binzhou Medical University Hospital, Binzhou, China
6 School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai, China
Universitair Kinderziekenhuis Koningin Fabiola: Hopital Universitaire des Enfants Reine Fabiola, BELGIUM

EDITOR / REVIEWER

Inge Roggen